Insulet (NASDAQ:PODD) Earns “Outperform” Rating from Raymond James

Raymond James reiterated their outperform rating on shares of Insulet (NASDAQ:PODD) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $328.00 price objective on the medical instruments supplier’s stock, up from their prior price objective of $294.00.

PODD has been the topic of several other reports. Sanford C. Bernstein started coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. Stifel Nicolaus raised their target price on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday. Morgan Stanley boosted their price target on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. JPMorgan Chase & Co. upped their price target on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Finally, Wells Fargo & Company lifted their price objective on Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus price target of $289.06.

Insulet Stock Performance

PODD stock opened at $282.80 on Friday. The company has a market cap of $19.84 billion, a P/E ratio of 48.84, a price-to-earnings-growth ratio of 3.62 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet has a 1 year low of $160.19 and a 1 year high of $289.46. The stock’s fifty day moving average price is $272.98 and its 200-day moving average price is $247.87.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. On average, equities analysts forecast that Insulet will post 3.92 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Institutional Trading of Insulet

Several hedge funds have recently modified their holdings of PODD. Blue Trust Inc. increased its position in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. Venturi Wealth Management LLC grew its stake in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the 4th quarter worth about $36,000. Itau Unibanco Holding S.A. purchased a new stake in shares of Insulet during the 4th quarter valued at about $42,000. Finally, SRS Capital Advisors Inc. grew its position in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.